Recent Updates
Recently added Catalysts
SRPT Positive Sentiment

Sarepta Therapeutics to Announce First Quarter 2026 Financial Results

Key Takeaway: Sarepta Therapeutics, Inc. will announce its first quarter 2026 financial results on May 6, 2026, after market close. A conference call will follow at 4:30 p.m. E.T. to discuss these results. The event will be available via live webcast and archived for one year on the company's investor relations website.
Price reaction · baseline $20.68 (2026-04-21 close) · hit after-hours · clean, no other SRPT news in the window
day 0 close
-0.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Sarepta Therapeutics is a leader in precision genetic medicine.
  • The company is actively engaging with investors through a conference call.
  • Sarepta is focused on addressing rare diseases, particularly Duchenne muscular dystrophy.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+46%
120-day peak, hindsight
Typical move
16.8%
average across 4 past catalysts
Lead asset
Eteplirsen
Phase 3 · Muscular Dystrophy, Duchenne

Full Press Release Details

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2026 financial results after the Nasdaq Global Market closes on Wednesday, May 6, 2026. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss these results.
The event will be webcast live under the investor relations section of Sarepta's website athttps://investorrelations.sarepta.com/events-presentationsand following the event a replay will be archived there for one year. Interested parties participating by phone will need to register usingthis online form. After registering for dial-in details, all phone participants will receive an auto-generated e-mail containing a link to the dial-in number along with a personal PIN number to use to access the event by phone.

About Sarepta Therapeutics

Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold a leadership position in Duchenne muscular dystrophy (Duchenne) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases.

Internet Posting of Information

We routinely post information that may be important to investors in the 'For Investors' section of our website atwww.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.

Frequently Asked Questions

When will Sarepta announce its Q1 2026 financial results?

Sarepta will announce its Q1 2026 financial results on May 6, 2026.

How can I access the conference call?

The conference call can be accessed via a live webcast on Sarepta's investor relations website.

What is Sarepta's focus area?

Sarepta focuses on precision genetic medicine for rare diseases, especially Duchenne muscular dystrophy.

Will the conference call be recorded?

Yes, a replay of the conference call will be archived for one year on the website.

Last updated: Apr 22, 2026